Not checkedNot checked for notices yet.
Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil
Maria Cassia Jacintho Mendes-Corrêa, MD, PhD, Roseli Saraiva Moreira Bittar, MD, PhD, Norma Salmito, MD and 1 more
Brazilian Journal of Infectious Diseases · 2011
doi:10.1016/s1413-8670(11)70147-7 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Sudden hearing loss is defined as a sensorineural hearing loss, equal to or greater than 30 dB, at three or more consecutive frequencies, which takes place within 72 hours. Both peginterferon and ribavirin are well-known to be associated with significant adverse effects, but sudden hearing loss is uncommon. We report a 65-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon-alpha and ribavirin for chronic hepatitis C. Peginterferon and ribavirin may cause sudden hearing loss that may not recover after discontinuation of therapy. Immediate treatment for all possible etiologies is essential, along with targeted investigations and early referral for an Ear, Nose and Throat specialist. Physicians should be aware of the possible ototoxic effects of peginterferon and ribavirin combination therapy requiring appropriate surveillance. Keywords: hepatitis C, chronic, hearing loss, sudden, interferon-alpha
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.